Excellent Presentations at JSCO2017

TOP > About JSCO > Awards > Excellent Presentations at JSCO2017

Followings are the Excellent Presentations selected by the Program Committee from those presented at the 55th Annual Meeting of the Japan Society of Clinical Oncology (JSCO2017).

 View abstracts: http://jsco.members-web.com/55award_eng/


Number of presentations awarded the Excellent Presentations
48 (including 8 Best Presentations)


Head and neck cancer
  • BNCT for Head and Neck Cancer : The history of our institution
    Teruhito Aihara (Proton Medical Research Centre, University of Tsukuba)
Oral cancer
  • Investigation of new predictors for occult cervical lymph node metastasis in early-stage squamous cell carcinoma of the tongue 【Best Presentation】
    Nobuhiro Yamakawa (Department of Oral and Maxillofacial Surgery, School of Medicine, Nara Medical University) 
Breast cancer
  • Risk factors for febrile neutropenia in breast cancer patients receiving doxorubicin and cyclophosphamide chemotherapy
    Harumi Nakamori (University of Shizuoka School of Pharmaceutical Sciences Department of Clinical Pharmacology & Genetics)
  • The outcome of the recurrent breast cancer according to the tumor subtypes
    Eriko Tokunaga (National Hospital Organization Kyushu Cancer Center)
  • Analysis of body composition and application to nutrition counseling for breast cancer patients
    Keiko Ito (Department of Clinical Nutrition, Hiroshima Prefectural Hospital)
  • Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: Multimodal functional imaging and multiplex cytokine analysis
    Shigeto Ueda (Saitama Medical University International Medical Center Department of breast oncology)
Hepato-biliary-pancreatic cancers
  • Identification of genes involved in resistance of anti-tumor drugs in induced cancer stem-like sphere cells 【Best Presentation】
    Ryouichi Tsunedomi (Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University, Graduate School of Medicine)
  • Cases of surgical resection for pancreatic neuroendocrine tumor
    Mariko Kamiya (Department of Gastrointestinal Surgery, Kanagawa Cancer Center)
  • The significance of Yap1-Mob1 dysregulation in human primary liver cancer
    Keishi Sugimachi (Department of Hepatobiliary-pancreatic Surgery, National Kyushu Cancer Center; Department of Surgery, Kyushu University Beppu Hospital)
  • Strategy of postoperative surveillance after IPMN resection based on the risk factors for the development of metachronous lesions in the remnant pancreas
    Tatsuo Hata (Department of Surgery, Tohoku University Graduate School of Medicine)
Esophageal cancer
  • Effect of perioperative oral care on prevention of postoperative pneumonia associated with esophageal cancer surgery: A multicenter case-control study with propensity score matching analysis 【Best Presentation】
    Soutome Sakiko (Perioperative Oral Management Center, Nagasaki University Hospital)
  • Influence of anti-inflammatory effect due to postoperative ghrelin administration after radical esophagactomy on prognosis of patients with esophageal cancer
    Yasuhiro Miyazaki (Division of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University)
  • Prevention of atrial fibrillation using landiolol hydrochloride after esophagectomy for esophageal cancer: A randomized, double-blind, placebo-controlled trial
    Toshiyasu Ojima (Second Department of Surgery, Wakayama Medical University, School of Medicine)
  • Surgical outcome of elderly patients over 75 years old with esophageal cancer
    Norio Yukawa (Yokohama City University Gastroenterological Center, Department of Surgery;  Yokohama City University, Department of Surgery)
  • Impact of visceral obesity on clinicopathological characteristics in patients with esophageal squamous cell carcinoma
    Akihiko Okamura (Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
  • Efficacy of postoperative adjuvant cancer peptide vaccine for pN(+) thoracic esophageal SCC patients and its association with tumor microenvironment
    Takushi Yasuda (Department of Surgery, Kindai University Faculty of Medicine)
Gastric cancer
  • Multicenter phase II study of trastuzumab in combination with S-1 and docetaxel for HER2-positive advanced gastric cancer 【Best Presentation】
    Shunsuke Kagawa (Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science)
  • A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)
    Manabu Ohashi (Department of Gastroenterological Surgery, Cancer Institute Hospital)
  • Postoperative weight loss leads to a poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer
    Toru Aoyama (Department of Gastrointestinal Surgery, Kanagawa Cancer Center and Department of Surgery, Yokohama City University)
  • Effect of exosomes from scirrhous gastric carcinoma on the histologic findings of peritoneal tissue
    Tomohisa Okuno (Department of Surgical Oncology, Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine)
  • A biomarker analysis to predict the outcomes of patients with gastric cancer who received neoadjuvant chemotherapy. An Exploratory study of the randomized phase II COMPASS trial
    Takashi Oshima (Department of Surgery, Yokohama City University)
  • A multicenter cohort study of combination therapy with trastuzumab for HER2-positive advanced gastric cancer (KSCC1105)
    Masaaki Iwatsuki (Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University)
  • A phase II study of nab-paclitaxel in combination with ramucirumab in patients with unresectable advanced/recurrent gastric cancer refractory to first-line chemotherapy containing fluoropyrimidines
    Hideki Shimodaira (Department of Clinical Oncology, Tohoku University Hospital)
Colorectal cancer
  • Expression profile of microRNA as a prognostic biomarker in patients with stage II colorectal cancer 【Best Presentation】
    Hiroki Ochiai (Division of Colorectal Surgery, National Cancer Center Hospital)
  • Phase II study of FOLFOXIRI plus bevacizumab for metastatic colorectal cancer: QUATTRO study
    Kentaro Yamazaki (Shizuoka Cancer Center)
  • Clip-test Ver. 2, a novel and simple tool for monitoring the growth of oxaliplatin induced peripheral neuropathy
    Tadashi Onishi (Department of Gastrointestinal Surgery NTT Osaka Hospital)
  • Clinical impact of molecular positive lymph node status by OSNATM assay in colorectal cancer: A Prospective Multicenter Trial in Japan
    Tomohisa Furuhata (Division of Gastroenterological and General Surgery, St. Marianna University Toyoko Hospital)
  • RAS, BRAF and MSI status as a biomarker for adjuvant therapy after the curative resection of colorectal cancer
    Hideaki Miyauchi (Department od Frontier Surgery, Chiba Graduate School of Medicine)
  • Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colorectal cancer: Updated results of Japan Clinical Oncology Group study (JCOG0910)
    Nobuhiro Takiguchi (Chiba Cancer Center Gastrointestinal Surgery)
  • A Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer[HGCSG1401] : Analysis of tumor location
    Kazuteru Hatanaka (Department of Gastroenterology, Hakodate Municipal Hospital)
  • A Retrospective Cohort Study Evaluating the Safety and Efficacy of TAS-102 in Patients with Metastatic Colorectal Cancer [HGCSG1503]
    Satoshi Yuki (Department of Gastroenterology and Hepatology, Hokkaido University Hospital)
  • Analysis of postoperative respiratory function after laparoscopic colorectal surgery in COPD patients
    Naoyuki Toyota (Department of Surgery, School of Medicine, Keio University)
Gynecologic cancers
  • Efficacy of HPV vaccination against HPV infection in Japanese young women【Best Presentation】
    Risa Kudo (Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Science)
  • Statin induced tumor suppressor genes to sensitize cisplatin-resistant cells
    Chiho Koi (Department of Obstetrics and Gynecology, University of Occupational and Environmental Health)
  • Establishment and characterization of patient-derived xenografts of clear cell carcinoma of the ovary
    Hiroshi Asano (Hokkaido University Hospital Department of Gynecology)
  • Analysis of association of the number of board-certified gynecologic oncologist and 5-year survival ratio of cervical cancer patients in each hospital
    A Yagi (Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine)
Prostate and testicular cancers
  • Serum testosterone level is a useful biomarker to aid optimal treatment selection in men with castration-resistant prostate cancer
    Kohei Hashimoto (Dept. of Urology, Sapporo Medical University School of Medicine)
  • Long-term clinical outcome of whole pelvis irradiation for patients with very high-risk locally advanced prostate cancer using simultaneous integrated boost intensity-modulated radiation therapy
    Kenji Takayama (Kyoto University Graduate School of Medicine, Department of Radiation Oncology and Image-Applied Therapy)
  • The Impact of Tertiary Gleason Pattern 5 in 2014 ISUP/WHO New Grading System on Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer
    Masashi Kato (Department of Urology, Nagoya University Graduate School of Medicine)
Renal and urothelial cancers
  • Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma -Sub analysis of the multi-institutional national database of the Japanese Urological Association【Best Presentation】
    Nobuyuki Nakajima (The Cancer Registration Committee of the Japanese Urological  Association, Tokai University Faculty of Medicine Department of Urology)
  • Mitochondrial ND1 mutations were associated with postoperative prognosis of localized renal cell carcinoma
    Hakushi Kim (Tokai University School of Medicine Department of Urology)
  • Developing a novel diagnostic model for bone metastases in renal cell carcinoma patients using computer-assisted diagnosis system for bone scans and bone turnover markers
    Takeshi Ujike (Department of Urology, Osaka University Graduate School of Medicine)
  • FDG PET/CT as a prognostic biomarker for the patients with advanced renal cell carcinoma after first molecular targeted therapy
    Noboru Nakaigawa (Yokohama City University Graduate School of Medicine)
Sarcomas of the soft tissues and bone
  • Analyzing multiple risk factors in patients with bone and soft tissue sarcoma : A case-control study
    Y Araki (Department of Orthopaedic Surgery, Graduate School of Medicine Sciences, Kanazawa University; Division of Musculoskeletal Oncology, National Cancer Center Hospital)
  • New challenges in the clinical development of drugs for rare cancers -Investigator Initiated Trials for rare cancers-
    Tadaaki Nishikawa (National Cancer Center Hospital, Department of Breast and Medical Oncology; Saitama Medical University International Medical Center, Department of Gynecologic Oncology)
Family cancer syndromes
  • High precision assay system of BRCA1/2 variants and copy number alterations by next generation sequencing analysis
    Yosuke Hirotsu (Genome Analysis Center, Yamanashi Central Hospital)
Lymph node metastasis
  • Creation of a lung metastasis activation mouse model by dissection of tumor-bearing lymph nodes【Best Presentation】
    Sachiko Horie (Tohoku University)
Patient advocacy
  • Cancer families’ concerns and information support from the questionnaire survey of cancer patients’ view
    Masayo Hayakawa (Center for Cancer Control and Information Services, National Cancer Center)


Past Presentation Awards